Skip to content
Triangle logo TriangleGet started
← Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas

HEALTH PROFESSIONAL · SOURCE READING

Biological therapy

Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 19, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome / Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome

Interferon alfa alone or in combination with other agents, such as topical therapy.[27,28]

Source links and citations

Interferon alfa alone or in combination with other agents, such as topical therapy.[27,28]

A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared the TTNT between patients who received interferon alfa and conventional chemotherapy. Interferon alfa provided a longer TTNT of 8.7 months (95% CI, 6.0–18.0) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1) (P < .00001).[29][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice